JP2020515581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515581A5 JP2020515581A5 JP2019553220A JP2019553220A JP2020515581A5 JP 2020515581 A5 JP2020515581 A5 JP 2020515581A5 JP 2019553220 A JP2019553220 A JP 2019553220A JP 2019553220 A JP2019553220 A JP 2019553220A JP 2020515581 A5 JP2020515581 A5 JP 2020515581A5
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine kinase
- kinase inhibitor
- population
- genetically engineered
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 22
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 15
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 15
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 230000011664 signaling Effects 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 4
- 150000004922 Dasatinib derivatives Chemical group 0.000 claims 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 3
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims 3
- 238000002659 cell therapy Methods 0.000 claims 3
- 229960002448 dasatinib Drugs 0.000 claims 3
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims 3
- 229960001131 ponatinib Drugs 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000001890 transfection Methods 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 230000033540 T cell apoptotic process Effects 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023011257A JP2023055805A (ja) | 2017-03-31 | 2023-01-27 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024123405A JP2024153812A (ja) | 2017-03-31 | 2024-07-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479930P | 2017-03-31 | 2017-03-31 | |
| US62/479,930 | 2017-03-31 | ||
| PCT/US2018/025394 WO2018183842A1 (en) | 2017-03-31 | 2018-03-30 | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023011257A Division JP2023055805A (ja) | 2017-03-31 | 2023-01-27 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515581A JP2020515581A (ja) | 2020-05-28 |
| JP2020515581A5 true JP2020515581A5 (cg-RX-API-DMAC7.html) | 2021-05-06 |
| JP7278961B2 JP7278961B2 (ja) | 2023-05-22 |
Family
ID=63677091
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553220A Active JP7278961B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2019553214A Active JP7249287B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2022193805A Active JP7674328B2 (ja) | 2017-03-31 | 2022-12-02 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2023011257A Pending JP2023055805A (ja) | 2017-03-31 | 2023-01-27 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024123405A Pending JP2024153812A (ja) | 2017-03-31 | 2024-07-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024200383A Pending JP2025026930A (ja) | 2017-03-31 | 2024-11-18 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553214A Active JP7249287B2 (ja) | 2017-03-31 | 2018-03-30 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2022193805A Active JP7674328B2 (ja) | 2017-03-31 | 2022-12-02 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
| JP2023011257A Pending JP2023055805A (ja) | 2017-03-31 | 2023-01-27 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024123405A Pending JP2024153812A (ja) | 2017-03-31 | 2024-07-30 | Ｔ細胞受容体のシグナル伝達を阻害するまたは調節することによってｔ細胞の疲弊を治療する方法 |
| JP2024200383A Pending JP2025026930A (ja) | 2017-03-31 | 2024-11-18 | Ｔ細胞受容体シグナル伝達を阻害または調節することによって、ｔ細胞枯渇を処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11938153B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3600323A4 (cg-RX-API-DMAC7.html) |
| JP (6) | JP7278961B2 (cg-RX-API-DMAC7.html) |
| CN (3) | CN110582280B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2018243571B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3057372A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2018183842A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111699001A (zh) * | 2017-12-07 | 2020-09-22 | 尤利乌斯·马克西米利安维尔茨堡大学 | 达沙替尼和其他酪氨酸激酶抑制剂对基因修饰的嵌合抗原受体t细胞的功能的控制和调节 |
| US20210393628A1 (en) * | 2018-10-30 | 2021-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating t cell exhaustion |
| EP3876958A1 (en) * | 2018-11-08 | 2021-09-15 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| AU2020231810B2 (en) * | 2019-03-01 | 2025-12-18 | National University Of Singapore | Engineered immune cells |
| CN110157680A (zh) * | 2019-05-08 | 2019-08-23 | 浙江大学 | 提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法 |
| WO2021020564A1 (ja) * | 2019-08-01 | 2021-02-04 | 国立大学法人三重大学 | Ｇｄ２結合性分子 |
| CA3158133A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| MX2022015764A (es) * | 2020-06-19 | 2023-01-19 | Chugai Pharmaceutical Co Ltd | Molecula de union al antigeno anti-celulas t para usarse en combinacion con un inhibidor de angiogenesis. |
| KR20230074146A (ko) * | 2020-09-24 | 2023-05-26 | 에프. 호프만-라 로슈 아게 | T 세포 이중특이성 항체 관련 역효과의 예방 또는 완화 |
| US20240108721A1 (en) * | 2020-10-30 | 2024-04-04 | The University Of North Carolina At Chapel Hill | Dual targeting chimeric antigen receptors |
| JPWO2022210487A1 (cg-RX-API-DMAC7.html) * | 2021-03-29 | 2022-10-06 | ||
| EP4071248A1 (en) | 2021-04-07 | 2022-10-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
| WO2022234063A1 (en) * | 2021-05-07 | 2022-11-10 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Method for constitutive malt1 protease activation |
| CN113533729B (zh) * | 2021-06-15 | 2024-09-06 | 北京大学人民医院 | 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用 |
| JP2024525727A (ja) | 2021-07-14 | 2024-07-12 | ２セブンティ バイオ インコーポレイテッド | 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体 |
| CN115677861A (zh) * | 2021-07-29 | 2023-02-03 | 上海科技大学 | 一种泛素偶联修饰的嵌合抗原受体及免疫细胞 |
| WO2023077026A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| WO2023077032A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing c-jun |
| KR20250008809A (ko) | 2022-04-08 | 2025-01-15 | 리제너론 파마슈티칼스 인코포레이티드 | 다분할 수용체 및 신호전달 복합체 |
| JP2025520384A (ja) * | 2022-06-13 | 2025-07-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 改善されたグリカン依存性キメラ抗原受容体細胞 |
| GB202218144D0 (en) * | 2022-12-02 | 2023-01-18 | Univ Oxford Innovation Ltd | Product |
| CN116121196B (zh) * | 2022-12-23 | 2025-07-22 | 广州安捷生物医学技术有限公司 | 一种调控car-t细胞的方法与应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2168456T3 (es) | 1995-01-16 | 2002-06-16 | North Sydney Area Health Serv | Peptidos que afectan a los linfocitos t. |
| US20050070478A1 (en) | 1996-06-11 | 2005-03-31 | Northern Sydney Area Health Services | T cell antigen receptor peptides |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| GB0523954D0 (en) | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
| US9334330B2 (en) | 2006-10-10 | 2016-05-10 | Universite De Nantes | Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers |
| US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| EP2664916B1 (en) | 2007-04-02 | 2017-02-08 | Acoustic Cytometry Systems, Inc. | Method for manipulating a fluid medium within a flow cell using acoustic focusing |
| EP3467101A3 (en) | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| TR201815488T4 (tr) | 2011-04-08 | 2018-11-21 | Health | Anti-epidermal büyüme faktör reseptörü varyant III kimerik antijen reseptörleri ve kanser tedavisi için kullanımı. |
| PT4223311T (pt) | 2011-05-24 | 2025-08-21 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacinas individualizadas para o cancro |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| US9347113B2 (en) * | 2011-12-02 | 2016-05-24 | Stillwater Mining Company | Precious metals recovery |
| NZ700362A (en) | 2012-04-11 | 2016-09-30 | Us Health | Chimeric antigen receptors targeting b-cell maturation antigen |
| WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| PT3300745T (pt) | 2013-02-15 | 2019-11-27 | Univ California | Recetor de antigénio quimérico e métodos de utilização do mesmo |
| ES2760023T3 (es) | 2013-02-20 | 2020-05-12 | Univ Pennsylvania | Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado |
| US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
| WO2014160627A1 (en) | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
| WO2014186469A2 (en) | 2013-05-14 | 2014-11-20 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| CN106535925A (zh) * | 2014-05-23 | 2017-03-22 | 佛罗里达大学研究基金会有限公司 | 基于car的免疫治疗 |
| CR20170014A (es) * | 2014-07-16 | 2017-10-17 | Hoffmann La Roche | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| WO2016028896A1 (en) | 2014-08-19 | 2016-02-25 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| US20170239294A1 (en) | 2014-10-15 | 2017-08-24 | Novartis Ag | Compositions and methods for treating b-lymphoid malignancies |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| EP3259352A4 (en) * | 2015-02-19 | 2018-12-05 | University of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| EP3270936A4 (en) * | 2015-03-17 | 2018-08-08 | Chimera Bioengineering Inc. | Smart car devices, de car polypeptides, side cars and uses thereof |
| GB201514328D0 (en) | 2015-08-12 | 2015-09-23 | Sigmoid Pharma Ltd | Compositions |
| WO2017127755A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CN109715207B (zh) * | 2016-03-29 | 2023-03-31 | 南加利福尼亚大学 | 靶向癌症的嵌合抗原受体 |
| EP3443096B1 (en) | 2016-04-15 | 2023-03-01 | Novartis AG | Compositions and methods for selective expression of chimeric antigen receptors |
| WO2018106595A1 (en) | 2016-12-05 | 2018-06-14 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CN111699001A (zh) * | 2017-12-07 | 2020-09-22 | 尤利乌斯·马克西米利安维尔茨堡大学 | 达沙替尼和其他酪氨酸激酶抑制剂对基因修饰的嵌合抗原受体t细胞的功能的控制和调节 |
| US20210393628A1 (en) * | 2018-10-30 | 2021-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating t cell exhaustion |
-
2018
- 2018-03-30 CN CN201880028993.XA patent/CN110582280B/zh active Active
- 2018-03-30 CN CN202410272411.XA patent/CN118161496A/zh active Pending
- 2018-03-30 JP JP2019553220A patent/JP7278961B2/ja active Active
- 2018-03-30 AU AU2018243571A patent/AU2018243571B2/en active Active
- 2018-03-30 CN CN201880029045.8A patent/CN110603044B/zh active Active
- 2018-03-30 WO PCT/US2018/025394 patent/WO2018183842A1/en not_active Ceased
- 2018-03-30 WO PCT/US2018/025459 patent/WO2018183888A2/en not_active Ceased
- 2018-03-30 US US16/499,760 patent/US11938153B2/en active Active
- 2018-03-30 EP EP18775932.9A patent/EP3600323A4/en active Pending
- 2018-03-30 AU AU2018243664A patent/AU2018243664B2/en active Active
- 2018-03-30 CA CA3057372A patent/CA3057372A1/en active Pending
- 2018-03-30 EP EP18777667.9A patent/EP3600357A4/en active Pending
- 2018-03-30 JP JP2019553214A patent/JP7249287B2/ja active Active
- 2018-03-30 CA CA3057505A patent/CA3057505A1/en active Pending
- 2018-03-30 US US16/499,762 patent/US20200101108A1/en active Pending
-
2022
- 2022-12-02 JP JP2022193805A patent/JP7674328B2/ja active Active
-
2023
- 2023-01-27 JP JP2023011257A patent/JP2023055805A/ja active Pending
-
2024
- 2024-02-21 US US18/583,096 patent/US20240293461A1/en active Pending
- 2024-06-07 AU AU2024203919A patent/AU2024203919A1/en active Pending
- 2024-07-30 JP JP2024123405A patent/JP2024153812A/ja active Pending
- 2024-11-18 JP JP2024200383A patent/JP2025026930A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515581A5 (cg-RX-API-DMAC7.html) | ||
| Sun et al. | Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer | |
| Ma et al. | Tumor necrosis factor α blockade exacerbates murine psoriasis‐like disease by enhancing Th17 function and decreasing expansion of Treg cells | |
| Bobrowicz et al. | Pathogenesis and therapy of primary cutaneous T-cell lymphoma: Collegium Internationale Allergologicum (CIA) update 2020 | |
| Wang et al. | The JAK inhibitor tofacitinib ameliorates immune-mediated liver injury in mice | |
| Marvin et al. | TGF‐β signaling in liver metastasis | |
| Climent et al. | Immunomodulatory activity of tyrosine kinase inhibitors to elicit cytotoxicity against cancer and viral infection | |
| JP2019065028A5 (cg-RX-API-DMAC7.html) | ||
| Lentsch et al. | Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2 | |
| RU2018136877A (ru) | Способы раннего вмешательства для профилактики или улучшения состояния токсичности | |
| Buechler et al. | Cutting edge: direct sensing of TLR7 ligands and type I IFN by the common myeloid progenitor promotes mTOR/PI3K-dependent emergency myelopoiesis | |
| Deng et al. | Pro-inflammatory T-lymphocytes rapidly infiltrate into the brain and contribute to neuronal injury following cardiac arrest and cardiopulmonary resuscitation | |
| Kang et al. | Regulatory mechanisms and their therapeutic implications of interleukin-12 production in immune cells | |
| Zhang et al. | Matrix metalloproteinase-9 and stromal cell-derived factor-1 act synergistically to support migration of blood-borne monocytes into the injured spinal cord | |
| Schiller et al. | Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer | |
| Seelige et al. | Mechanisms regulating immune surveillance of cellular stress in cancer | |
| Aram et al. | Granulocyte-macrophage colony-stimulating factor as a therapeutic target in multiple sclerosis | |
| Johnson‐Ansah et al. | Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia | |
| Wosik et al. | Death receptor expression and function at the human blood brain barrier | |
| Hazlett et al. | Reviews for immune privilege in the year 2010: immune privilege and infection | |
| Levi et al. | Continuous stress disrupts immunostimulatory effects of IL-12 | |
| Naessens et al. | CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity | |
| Cocco et al. | Anti-leukemic properties of IL-12, IL-23 and IL-27: differences and similarities in the control of pediatric B acute lymphoblastic leukemia | |
| Fazzi et al. | Phase II trial of maintenance treatment with IL2 and zoledronate in multiple myeloma after bone marrow transplantation: biological and clinical results | |
| McQueen et al. | Natural killer group 2D and CD 28 receptors differentially activate mammalian/mechanistic target of rapamycin to alter murine effector CD 8+ T‐cell differentiation |